Haematopathology Section, Hospital Clínic of Barcelona, Institut d'Investigaciones Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Centro de Investigación Biomédica en Red de Cancer (CIBERONC), Barcelona, Spain.
Hematopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD.
Blood. 2022 Sep 15;140(11):1229-1253. doi: 10.1182/blood.2022015851.
Since the publication of the Revised European-American Classification of Lymphoid Neoplasms in 1994, subsequent updates of the classification of lymphoid neoplasms have been generated through iterative international efforts to achieve broad consensus among hematopathologists, geneticists, molecular scientists, and clinicians. Significant progress has recently been made in the characterization of malignancies of the immune system, with many new insights provided by genomic studies. They have led to this proposal. We have followed the same process that was successfully used for the third and fourth editions of the World Health Organization Classification of Hematologic Neoplasms. The definition, recommended studies, and criteria for the diagnosis of many entities have been extensively refined. Some categories considered provisional have now been upgraded to definite entities. Terminology for some diseases has been revised to adapt nomenclature to the current knowledge of their biology, but these modifications have been restricted to well-justified situations. Major findings from recent genomic studies have impacted the conceptual framework and diagnostic criteria for many disease entities. These changes will have an impact on optimal clinical management. The conclusions of this work are summarized in this report as the proposed International Consensus Classification of mature lymphoid, histiocytic, and dendritic cell tumors.
自 1994 年修订的欧洲-美国淋巴肿瘤分类发布以来，通过血液病理学家、遗传学家、分子科学家和临床医生之间的反复国际努力，已经产生了淋巴肿瘤分类的后续更新，以实现广泛共识。最近，免疫系统恶性肿瘤的特征取得了重大进展，基因组研究提供了许多新的见解。这导致了本提案的产生。我们遵循了与世界卫生组织第三和第四版血液肿瘤分类成功使用的相同过程。许多实体的定义、推荐的研究和诊断标准已经得到了广泛的改进。一些以前被认为是临时性的类别现在已经升级为确定的实体。一些疾病的术语已经被修订，以适应其生物学的当前知识，但这些修改仅限于有充分理由的情况。最近基因组研究的主要发现影响了许多疾病实体的概念框架和诊断标准。这些变化将对最佳临床管理产生影响。这项工作的结论总结在本报告中，作为成熟淋巴、组织细胞和树突状细胞肿瘤的国际共识分类建议。
